The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism

What Was Tested

This randomized controlled trial paper looks at Parathyroid Hormone (PTH 1-84) in the context of hyperparathyroidism.

Treatment with vitamin D sterols can lower plasma parathyroid hormone (PTH) in many patients with secondary hyperparathyroidism due to end-stage renal disease, but hypercalcemia, hyperphosphatemia, or both often develop during treatment.

As such, alternative therapeutic approaches to managing excess PTH secretion are needed.

Who Took Part

By PubMed's age tags, the people studied were adults.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Parathyroid Hormone (PTH 1-84) and who got the comparison, which limits bias.

As a double-blind Parathyroid Hormone (PTH 1-84) study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Parathyroid Hormone (PTH 1-84) group a baseline to be compared against.

What Was Measured

Treatment with vitamin D sterols can lower plasma parathyroid hormone (PTH) in many patients with secondary hyperparathyroidism due to end-stage renal disease, but hypercalcemia, hyperphosphatemia, or both often develop during treatment.

The subject headings attached to it are Calcium, Cinacalcet, Hyperparathyroidism, Secondary, Kidney Failure, Chronic, Naphthalenes, Osmolar Concentration and Parathyroid Hormone.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Parathyroid Hormone (PTH 1-84) in people with hyperparathyroidism.

The publication is from 2002 (Journal of the American Society of Nephrology : JASN), a journal based in United States.

More context: the Parathyroid Hormone (PTH 1-84) compound page, Hyperparathyroidism research.